Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2015-10-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives: The purpose of this study was to evaluate drug deposition of different types of nebulizers testing with breathing patterns of healthy subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhaled Dose Analysis Using a Breath Actuated Nebulizer in Healthy Subjects
NCT06157515
National Mobile Asthma Management System-E Project
NCT02917174
3D-Printed Aerosolized Medication Delivery Assist Device in Patients With Chronic Respiratory Diseases
NCT06315374
Asthma and Quantifying Delivery Of Radio Labeled Aerosol
NCT01823926
Breath Actuated Nebulizer Study Protocol
NCT00382447
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study was approved by Chang Gung Memorial Foundation Institutional Review Broad. Ten healthy subjects, aged 20.6±0.5 years, were recruited. Four nebulizers:
1. a constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan);
2. a breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany);
3. a manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan); and
4. a breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) were evaluated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aerosolized drug depositions
Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
Constant jet nebulizer
A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Breath enhanced nebulizer
A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Manual-actuated nebulizer
A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Breath-actuated nebulizer
A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Constant jet nebulizer
A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Breath enhanced nebulizer
A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Manual-actuated nebulizer
A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Breath-actuated nebulizer
A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of asthma
* Drug allergy
* Pulmonary disease
* Heart disease
* Arrythmia
* Hyperthyroids
* Diabetes mellitus
* Lactacidosis
* Pregnant
* Under B-blocker medications
20 Years
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chang Gung University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hui-Ling Lin
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hui-Ling Lin, MSc
Role: PRINCIPAL_INVESTIGATOR
Chang Gung University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChangGungUniversity
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.